Pay in 4 interest-free payments of $6.75 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
doi: 10.4274/ejbh.galenos.2025.2024-10-2
A decision from the FDA is expected by spring 2026
IEC-EC added to Carvyktis boxed warning Condition may lead to gut perforation, sepsis, or death Treatment involves supportive care, immunosuppressants, and specialist referral FDA advises vigilance for delayed-onset adverse events postCAR T-cell therapy Despite these risks, the FDA reaffirmed that Carvyktis benefits outweigh its potential harms, citing strong survival outcomes in treated patients
Deletion of betaine-homocysteine S-methyltransferase in mice perturbs choline and 1-carbon metabolism, resulting in fatty liver and hepatocellular carcinomas
US$ 29.43
US$ 21.70
US$ 26.77
US$ 20.24
US$ 24.48
